New hope for tough cancers: early trial tests targeted drug combo

NCT ID NCT06287463

Summary

This early-stage clinical trial tested a new drug called DCC-3084, both alone and combined with other cancer therapies, for people with advanced solid tumors driven by specific genetic mutations. The study aimed to find a safe dose and see if the treatment could shrink tumors in patients who had run out of standard treatment options. The trial was terminated early and enrolled 29 participants with cancers like melanoma, lung, and pancreatic cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • NEXT Oncology Virginia

    Fairfax, Virginia, 22031, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

  • SCRI Florida Cancer Specialists

    Orlando, Florida, 32827, United States

  • SCRI HealthONE

    Denver, Colorado, 80218, United States

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94158, United States

  • University of Southern California - Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.